Combining BRAF Inhibitor And Immunotherapy Increases Antitumor Activity In Metastatic Melanoma
19:00 EDT 16 Aug 2012 | Medical News Today
BRAF Inhibitor Zelboraf Boosts Effectiveness of Immunotherapy in Mouse ModelCombining the recently approved BRAF inhibitor, Zelboraf with an engineered T cell immunotherapy to treat metastatic melanoma significantly increased tumor responses and surv..
Original Article: Combining BRAF Inhibitor And Immunotherapy Increases Antitumor Activity In Metastatic Melanoma
More From BioPortfolio on "Combining BRAF Inhibitor And Immunotherapy Increases Antitumor Activity In Metastatic Melanoma"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
